Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus DORYX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus DORYX.
ACTICLATE CAP vs DORYX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
100 mg orally every 12 hours on day 1, then 100 mg orally every 24 hours. For severe infections: 100 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Terminal elimination half-life is 18-22 hours in healthy adults; prolonged to 21-36 hours in renal impairment; clinically relevant for once-daily dosing and monitoring for accumulation.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Renal (40-60% as unchanged drug via glomerular filtration), biliary/fecal (20-30% as active and inactive metabolites), incomplete excretion leads to enterohepatic recirculation.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic